Prognosis of Non-small-cell Lung Cancer Patients With Lipid Metabolism Pathway Alternations to Immunotherapy

Prognosis of Non-small-cell Lung Cancer Patients With Lipid Metabolism Pathway Alternations to Immunotherapy

Immune checkpoint inhibitors (ICIs) significantly improve the survival of patients with non-small-cell lung cancer (NSCLC), but only some patients obtain clinical benefits. Predictive biomarkers for ICIs can accurately identify people who will benefit from immunotherapy. Lipid metabolism signaling p...

Full description

Bibliographic Details
Main Authors: Tianli Cheng, Jing Zhang, Danni Liu, Guorong Lai, Xiaoping Wen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Genetics
Subjects:
immune checkpoint inhibitors
non-small-cell lung cancer
predictive marker
lipid metabolism pathway
immune microenvironment
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2021.646362/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2021.646362/full

Similar Items